ZA200309841B - S-omeprazole (esomeprazole) inclusion complex with cyclodextrins. - Google Patents

S-omeprazole (esomeprazole) inclusion complex with cyclodextrins. Download PDF

Info

Publication number
ZA200309841B
ZA200309841B ZA200309841A ZA200309841A ZA200309841B ZA 200309841 B ZA200309841 B ZA 200309841B ZA 200309841 A ZA200309841 A ZA 200309841A ZA 200309841 A ZA200309841 A ZA 200309841A ZA 200309841 B ZA200309841 B ZA 200309841B
Authority
ZA
South Africa
Prior art keywords
inclusion complex
omeprazole
cyclodextrin
complex
solution
Prior art date
Application number
ZA200309841A
Other languages
English (en)
Inventor
Yusuf Khwaja Hamied
Dharmaraj Ramachandra Rao
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ZA200309841B publication Critical patent/ZA200309841B/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ZA200309841A 2001-06-06 2003-12-19 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins. ZA200309841B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex

Publications (1)

Publication Number Publication Date
ZA200309841B true ZA200309841B (en) 2005-03-14

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200309841A ZA200309841B (en) 2001-06-06 2003-12-19 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins.

Country Status (17)

Country Link
US (1) US20040147481A1 (https=)
EP (1) EP1401442B1 (https=)
JP (1) JP2004536810A (https=)
AT (1) ATE282412T1 (https=)
AU (1) AU2002344386B2 (https=)
CA (1) CA2449769C (https=)
DE (1) DE60201995T2 (https=)
ES (1) ES2232780T3 (https=)
GB (1) GB2376231A (https=)
LT (1) LT5182B (https=)
LV (1) LV13154B (https=)
NZ (1) NZ529956A (https=)
PL (1) PL366940A1 (https=)
PT (1) PT1401442E (https=)
RU (1) RU2313343C2 (https=)
WO (1) WO2002098423A1 (https=)
ZA (1) ZA200309841B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 s-오메프라졸 함유 포접 복합체 및이의 제조방법
ATE428707T1 (de) 2005-12-28 2009-05-15 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
WO2009040825A1 (en) 2007-09-25 2009-04-02 Hetero Drugs Limited A process for preparation of enantiomerically pure esomeprazole
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (https=) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
WO1998040069A2 (en) * 1997-03-13 1998-09-17 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
ES2149750T3 (es) * 1999-01-06 2004-06-01 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos.
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
DE60023154T2 (de) * 1999-08-26 2006-06-22 Aaipharma Inc. Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Also Published As

Publication number Publication date
LT2003100A (en) 2004-09-27
CA2449769A1 (en) 2002-12-12
ES2232780T3 (es) 2005-06-01
EP1401442B1 (en) 2004-11-17
RU2313343C2 (ru) 2007-12-27
LV13154B (en) 2004-07-20
JP2004536810A (ja) 2004-12-09
CA2449769C (en) 2010-12-14
PL366940A1 (en) 2005-02-07
LT5182B (lt) 2004-12-27
PT1401442E (pt) 2005-02-28
GB2376231A (en) 2002-12-11
AU2002344386B2 (en) 2006-11-30
ATE282412T1 (de) 2004-12-15
HK1064602A1 (en) 2005-02-04
US20040147481A1 (en) 2004-07-29
EP1401442A1 (en) 2004-03-31
RU2003137221A (ru) 2005-06-10
GB0113792D0 (en) 2001-07-25
DE60201995T2 (de) 2005-11-24
DE60201995D1 (de) 2004-12-23
NZ529956A (en) 2005-07-29
WO2002098423A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
US6410569B1 (en) Salt form of pantoprazole
HUP0400781A2 (hu) Eljárás (R)- vagy (S)-lansoprazol kristályosítására, az előállított kristályok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2002012225A1 (en) Salts of benzimidazole compound and use thereof
WO2001002389A1 (en) Crystals of benzimidazole compounds
EP1018340B1 (en) Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them
EP1401442B1 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
AU2002344386A1 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
KR100619200B1 (ko) 개선된 화학적 제조 방법 및 제약 제형
JP3283252B2 (ja) ベンズイミダゾール化合物の結晶
DE602004011946T2 (de) Alkalisalze von protonenpumpen-hemmern
HK1064602B (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
WO2005070426A1 (en) Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection
JP2001072675A (ja) ベンズイミダゾール化合物の結晶
US20090030044A1 (en) Crystal of Salt of Benzimidazole Compound
JP2008505160A (ja) (s)−オメプラゾールのマグネシウム塩の固形形態とその製造方法
DE10234617B4 (de) Neues Salz von (S)-Pantoprazol
JP2001122783A (ja) ベンズイミダゾール化合物の結晶
CH697390B1 (de) Orale pharmazeutische Formulierung für Pyridylmethylsulfinyl-Benzimidazole und Verfahren zu ihrer Herstellung.